Advances in™ Schizophrenia: The Role of Emerging Therapies in Improving Safety and Medication Adherence

Released On
July 29, 2020

Expires On
February 10, 2022

Media Type

Completion Time
60 minutes



Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

Supported by an educational grant from Alkermes, Inc.

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — maximum of 1.0 Contact Hours

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This online educational activity is directed primarily toward psychiatrists. Additional health care professionals involved in patient care of schizophrenia, such as NPs, PAs, and PCPs, will also be invited to participate.

Program Overview

This online educational activity is designed to provide expert interpretation of new and emerging data on the treatment of schizophrenia, with a forward-looking perspective on how new and novel agents might impact clinical practice. A review of unmet needs related to relapse due to medical nonadherence as well as an exploration of emerging agents that hold promise for overcoming limitations associated with current antipsychotic therapies will be presented in a multimedia format, including a series of video interviews with an expert thought leader integrated into text-based elements.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Recognize unmet needs in schizophrenia treatment and factors that contribute to relapse, including the association between metabolic or other medication adverse effects and treatment nonadherence
  • Assess the role of emerging therapies in meeting the unmet needs of patients with schizophrenia based on available efficacy and safety data
  • Understand the importance of a comprehensive, holistic, multidisciplinary treatment plan in preventing relapse and improving outcomes in patients with schizophrenia


Christoph U. Correll, MD

Christoph U. Correll, MD

Medical Director, Recognition and Prevention (RAP) Program
The Zucker Hillside Hospital, Department of Psychiatry
Northwell Health
Glen Oaks, NY
Professor of Psychiatry and Molecular Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Department of Psychiatry and Molecular Medicine
Hempstead, NY
Investigator, The Feinstein Institutes for Medical Research
Center for Psychiatric Neuroscience
Manhasset, NY
Professor of Child and Adolescent Psychiatry, Charité
Universitätsmedizin Berlin
Department of Child and Adolescent Psychiatry
Berlin, Germany

René S. Kahn, MD, PhD

René S. Kahn, MD, PhD

Esther and Joseph Klingenstein Professor & Chair
Department of Psychiatry and Behavioral Health System
Icahn School of Medicine at Mount Sinai
New York, NY
VISN 2 Mental Illness Research Education and Clinical Center (MIRECC)
James J. Peters Veterans Affairs Medical Center
Bronx, NY
Professor of Psychiatry
University Utrecht
The Netherlands

Accreditation Statement

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 1.0 Contact Hour.

Disclosures of Conflicts of Interest

In accordance with ACCME guidelines, PER® has identified and resolved all conflicts of interest for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Christoph U. Correll, MD

  • Grant/Research Support: Janssen, Takeda. Consultant: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda, and Teva
  • Stock/ Shareholder: LB Pharma

René S. Kahn, MD, PhD

  • Consultant: Alkermes, Otsuka, Janssen-Cilag, Luye Pharma, Sunovion

The staff of Physicians’ Education Resource®, LLC (PER®), have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME credit participants must:

  1. Complete the activity (including pre- and postactivity assessments).
  2. Answer the evaluation questions.
  3. Request credit using the drop-down menu.
You may immediately download your certificate.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.